8-K: BriaCell Therapeutics Subsidiary, BriaPro Therapeutics, Files Interim Financials

BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., has filed its unaudited condensed interim consolidated financial statements and management's discussion and analysis for the three and six month periods ended January 31, 2025.

Summary

• BriaPro Therapeutics Corp., a two-thirds owned subsidiary of BriaCell Therapeutics Corp., filed its unaudited condensed interim consolidated financial statements for the periods ending January 31, 2025.
• The company reported a net loss of $233,185 for the six months ended January 31, 2025.
• Research and development expenses for the six months were $130,023, a decrease from $168,563 in the same period of 2024.
• General and administrative expenses totaled $80,012 for the six months, compared to $88,494 in the prior year.
• The company's ability to continue as a going concern is dependent on obtaining future profitable operations and securing necessary financing.
• BriaPro is developing Bria-TILsRx and protein kinase C delta (PKC) inhibitors for cancer treatment.
• The company is using AI to guide the design of novel multi-specific binding reagents known as Bria-TILsRx and to enhance the selectivity and potency of novel protein kinase C delta inhibitors.
• Human clinical studies for Bria-TILsRx are expected to begin in the first half of 2025, and for PKC inhibitors in the second half of 2025.
• As of January 31, 2025, the total balance owing to BriaCell group companies is $658,049.
• The company has a negative working capital of $658,048 as of January 31, 2025.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the reported net loss and negative working capital, offset by the company's ongoing research and development efforts and potential for future growth in the cancer therapeutics market.

Positives

• Research and development expenses decreased from $168,563 to $130,023 for the six-month period, indicating potential cost management.
• General and administrative expenses decreased slightly from $88,494 to $80,012 for the six-month period.
• The company is actively developing novel immunotherapies and PKC inhibitors for cancer treatment, indicating a focus on innovation.
• BriaPro is using AI to guide drug design, which could accelerate the drug discovery process.

Negatives

• The company reported a net loss of $233,185 for the six months ended January 31, 2025.
• The company has a negative working capital of $658,048 as of January 31, 2025.
• The company's ability to continue as a going concern is dependent on obtaining future profitable operations and securing necessary financing.
• The company is reliant on BriaCell for financing its operations.

Risks

• The company's ability to continue as a going concern is dependent on obtaining future profitable operations and securing necessary financing.
• The company is reliant on BriaCell for financing its operations.
• The company has a limited operating history and no operating revenues.
• The clinical effectiveness and safety of any of BriaPro's developmental products is not yet supported by extensive clinical data.
• The market for cancer therapeutics is highly competitive.
• The company may be subject to claims that it has used or disclosed trade secrets or other proprietary information of former employers.
• The company's intellectual property is currently under third-party licenses and may require additional third-party licenses to effectively develop and manufacture its key products or future technologies.
• The company is subject to risks associated with regulatory changes, privacy and data regulation, and product liability.

Future Outlook

BriaPro expects to screen several different multi specific binding reagents for activity in vitro as well as in mouse models of cancer over the next year and expects to select at least one candidate to advance into IND enabling studies. Human clinical studies are expected to be initiated in the first half of 2025. In parallel, BriaPro will continue to optimize the structure of its proprietary protein kinase C delta inhibitors and advance to the candidates election stage. Human clinical studies are expected to be initiated in the second half of 2025.

Management Comments

• Management is satisfied that these Unaudited Condensed Interim Consolidated Financial Statements have been fairly presented.
• Management believes that the credit risk concentration with respect to financial instruments is remote.

Industry Context

BriaPro operates in the competitive cancer therapeutics market, focusing on immunotherapies and targeted approaches. The company is leveraging AI for drug discovery, aligning with a growing trend in the pharmaceutical industry.

Comparison to Industry Standards

• The global cancer immunotherapy market was estimated at $115 billion in 2022, indicating a large potential market for BriaPro's Bria-TILsRx.
• The company's approach of using a quadrivalent platform to develop immunotherapies differentiates it from competitors using bi-specific T cell engagers (BITEs) like BLINCYTO and KIMMTRAK.
• BriaPro's focus on small molecules that combat RAS transformed tumors and protein kinase C delta inhibitors aligns with efforts to address 'undruggable' targets in cancer.

Related Party Transactions

• As of January 31, 2025, the total balance owing to BriaCell group companies is $658,049.
• For the six month period ending January 31, 2025 the fixed monthly services expense totaled $120,000 and direct expenses incurred by Briacell on behalf of BriaPro totaled $113,395.
• During the six month period ended January 31, 2025, the Company incurred Services and direct expense paid for by Briacell in the amount of $233,395.

Stakeholder Impact

• Shareholders may experience dilution due to potential future issuances of securities.
• Employees are subject to the risk of job insecurity due to the company's financial situation.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors face the risk of delayed or non-payment due to the company's financial constraints.

Next Steps

• Screening multi specific binding reagents for activity in vitro and in mouse models of cancer.
• Selecting a candidate to advance into IND enabling studies.
• Initiating human clinical studies for Bria-TILsRx in the first half of 2025.
• Optimizing the structure of proprietary protein kinase C delta inhibitors.
• Advancing to the candidates election stage for PKC inhibitors.
• Initiating human clinical studies for PKC inhibitors in the second half of 2025.

Key Dates